Maintains a stable financial position with recent positive interim results from a Phase 2 trial for Parkinson's disease immunotherapy.
Targets both genetic and acquired cardiac conditions, addressing significant unmet medical needs. Soligenix, Inc. (NASDAQ: SNGX) Focus: Rare diseases and specialized biodefense products.
While occasionally trading above the $5 threshold, it showed significant momentum in April 2026 with an 18.92% 12-week price change reported by Zacks. Key Risks for Investors biotech penny stocks to buy
Utilizing artificial intelligence to develop medicines in neuroscience and immuno-oncology.
Many of these companies are pre-revenue, meaning their valuation rests entirely on clinical trial outcomes and regulatory approvals . Maintains a stable financial position with recent positive
AI responses may include mistakes. For financial advice, consult a professional. Learn more Top Biotech Penny Stocks to Watch Out for in 2025
Below are notable biotech penny stocks and emerging players identified by analysts for their potential in 2026. High-Potential Biotech Penny Stocks Many of these companies are pre-revenue, meaning their
Clinical-stage firms often report net losses—such as Tenaya Therapeutics' reported $-94.26M—making them reliant on continuous fundraising.